Antithrombotic effects of abciximab.

Area of Science:

• Cardiovascular Medicine
• Hematology
• Pharmacology

Background:

• Platelet aggregation and thrombosis are regulated by the glycoprotein (GP) IIb/IIIa receptor complex.
• GP IIb/IIIa antagonists, like abciximab, interfere with this receptor complex and have shown effectiveness in clinical trials.
• Abciximab (c7E3 Fab fragment) was the first agent in this class to demonstrate benefits after coronary interventions.

Purpose of the Study:

• To investigate whether combining heparin with the GP IIb/IIIa antagonist abciximab enhances antithrombotic effects.
• To assess the additive antithrombotic potential of heparin when used alongside abciximab in patients on aspirin undergoing interventional procedures.

Main Methods:

• An ex vivo perfusion chamber model was used with blood from patients on aspirin undergoing interventional procedures.
• Blood was perfused over a severely injured arterial wall under conditions mimicking a mildly stenosed coronary artery.
• Treatments assessed included baseline, heparin alone, abciximab alone, and the combination of abciximab and heparin, with thrombus formation quantified.

Main Results:

• Heparin alone did not significantly alter baseline thrombus formation.
• Abciximab demonstrated a significant 58% reduction in thrombus formation compared to baseline (p <0.001).
• The addition of heparin to abciximab did not result in a further reduction in thrombus area compared to abciximab alone.

Conclusions:

• Abciximab effectively and significantly decreases mural thrombus formation.
• Combining heparin with abciximab does not provide additional antithrombotic benefits beyond abciximab monotherapy in this setting.
• These findings suggest that abciximab alone is sufficient for substantial antithrombotic effect in patients on aspirin undergoing interventions.